10.2 KEPI Immunization Schedule & Vaccine Logistics

KEPI Immunization Schedule & Vaccine Logistics

The Kenya Expanded Programme on Immunization (KEPI), coordinated under the National Vaccines and Immunization Program (NVIP) of the Ministry of Health, is one of Kenya's most cost-effective and impactful public health interventions. Immunization protects infants and young children against major infectious killers: tuberculosis, poliomyelitis, diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b invasive disease, pneumococcal pneumonia and meningitis, rotavirus enteritis, measles, rubella, yellow fever, and human papillomavirus-associated cervical malignancy.

For the Clinical Officers Council (COC) Pre-Internship Examination, candidates must demonstrate flawless recall of vaccination timetables, precise routes, dosages, and anatomical sites, alongside rigorous knowledge of the cold chain, freeze-damage detection (the Shake Test), and Vaccine Vial Monitor (VVM) interpretation.

---

1. Complete Kenya Immunization Timetable (Birth to 10 Years)

The table below details the official national schedule administered at Child Welfare Clinics (CWCs) across Kenya:

Three Schedule Changes That Took Effect on 1 November 2025

Kenya revised the routine schedule in the 2025/2026 financial year. Any revision material, chart booklet, or past paper printed before November 2025 is out of date on these three points, and they are exactly the kind of detail an examiner uses to separate current candidates from those revising off old notes:

• HPV single dose. WHO's Strategic Advisory Group of Experts concluded that one dose gives equally effective, durable protection against the oncogenic HPV types that cause cervical cancer. Kenya adopted this in November 2025. A single visit doubles the number of girls who can be protected with the same resources and removes the second-visit cost that drove most of the previous drop-off.
• IPV second dose (IPV 2) at 9 months. Added in line with WHO and Global Polio Eradication Initiative recommendations to strengthen type-2 humoral immunity as part of the polio endgame strategy. Note the practical consequence at the 9-month visit: the child now receives MR 1, IPV 2, yellow fever where applicable, and malaria dose 3 in endemic sub-counties. Use separate syringes and sites, and space injections at least 2.5 cm apart in the same limb.
• Malaria vaccine. Kenya was one of three Malaria Vaccine Implementation Programme pilot countries and introduced RTS,S/AS01 in 2019 in selected western sub-counties. From November 2025 the programme transitioned to the R21/Matrix-M formulation and expanded geographically. The schedule is a 4-dose series at 6, 7, 9 and 24 months, delivered only in designated malaria-endemic sub-counties — it is not a national-schedule vaccine, and dose 4 at 24 months is the dose most commonly missed because it falls outside the routine infant visits.

---

2. Technical Administration Guidelines & Clinical Nuances

BCG (Bacille Calmette-Guérin)

• Dilution & Storage: Reconstituted with supplied physiological saline diluent. Must be protected from direct sunlight (photolabile) and used within 6 hours of reconstitution.
• Injection Technique: Administered strictly intradermally on the right upper arm at the insertion of the deltoid, using a 26G or 27G short-bevel needle held bevel-up at a 10° to 15° angle to the skin. Correct administration produces a pale, blanched, pitted intradermal wheal measuring 5 to 8 mm ('orange-peel' appearance).
• Normal BCG Evolution:
  1. Immediate: Transient wheal that flattens within 30 minutes.
  2. 2 to 3 weeks: Indurated, erythematous papule develops at injection site.
  3. 5 to 6 weeks: Papule softens, ulcerates, and discharges serous fluid.
  4. 8 to 12 weeks: Ulcer spontaneously dries and forms a crust, leaving a permanent, flat or slightly depressed BCG scar measuring 3 to 7 mm.
• Clinical Pitfalls: Subcutaneous administration causes deep abscesses and suppurative regional axillary lymphadenitis (BCG-oma). Do not apply ointments, antibiotics, or bandages over the normal BCG lesion; counsel mother to leave it uncovered.

OPV vs. IPV Polio Eradication Strategy

• OPV (Bivalent Oral Poliovirus Vaccine): Contains attenuated type 1 and type 3 polioviruses. Secretes secretory IgA on the intestinal mucosa, preventing wild virus replication and gut shedding. It is delivered as 2 drops directly onto the child's tongue.
• OPV 0 (Birth Dose): Must be given within the first 14 days of life. If an infant presents after 14 days without OPV 0, do not give OPV 0; start directly with OPV 1 at 6 weeks.
• IPV (Inactivated Poliovirus Vaccine): Kenya now gives two doses — IPV 1 at 14 weeks and IPV 2 at 9 months, each 0.5 mL IM — following the schedule change of 1 November 2025. IPV contains inactivated types 1, 2, and 3 virus. Because type 2 was withdrawn from OPV to eliminate Vaccine-Associated Paralytic Poliomyelitis (VAPP) and circulating Vaccine-Derived Polioviruses (cVDPV), IPV provides the systemic humoral immunity against type 2 poliovirus that bivalent OPV cannot. The second dose was added because one dose leaves a measurable proportion of children seronegative to type 2.

Rotavirus Vaccine (ROTAVAC)

• Kenya utilizes the live attenuated monovalent 116E strain (ROTAVAC), administered as 5 drops orally at 6, 10, and 14 weeks. If an infant spits out the drops immediately, re-administer the dose once gently.

Measles-Rubella (MR 1 and MR 2)

• Given at 9 months (MR 1) and 18 months (MR 2) to address primary vaccine failure (approximately 10–15% of infants fail to seroconvert at 9 months due to lingering maternal transplacental antibodies). Administered subcutaneously into the right upper deltoid at a 45° angle using a 25G needle.

Malaria Vaccine (R21/Matrix-M)

• Who gets it: infants in designated malaria-endemic sub-counties only, concentrated in the lake-endemic and coastal-endemic zones. A child born in Nairobi or Turkana does not receive it on the routine schedule; a child in Homa Bay or Busia does.
• Schedule: 4 doses at 6, 7, 9 and 24 months, 0.5 mL IM into the anterolateral thigh.
• Why it starts at 6 months and not 6 weeks: efficacy in the 6–12-week co-administration age group was too low to justify infant-schedule delivery, so the series was designed to begin around 5–6 months.
• Counselling point: the vaccine reduces but does not abolish malaria risk. Insecticide-treated nets, indoor residual spraying, intermittent preventive treatment in pregnancy, and prompt testing and treatment all continue unchanged. Parents who believe a vaccinated child cannot get malaria present late with severe disease.

HPV Vaccine

• Single dose at 10 years for girls, from 1 November 2025 (previously 2 doses 6 months apart).
• Protects against the oncogenic HPV types responsible for the majority of cervical cancer, which remains a leading cancer killer of Kenyan women.
• Given intramuscularly into the deltoid. It is freeze-sensitive — never let it freeze.

Yellow Fever Endemic Counties in Kenya

Yellow fever vaccination is not universally administered across all 47 counties; it is routinely given at 9 months in designated high-risk counties along the Rift Valley and Lake Victoria basin: Baringo, Elgeyo Marakwet, West Pokot, Turkana, Kisumu, and Kericho.

3. Vaccine Cold Chain Logistics

The cold chain is the continuous, temperature-controlled supply chain system that ensures vaccines maintain their biochemical potency and immunological efficacy from the point of manufacture to the point of administration.

                         COLD CHAIN TEMPERATURE ZONES

   Temperature Level                 Vaccine Types Stored
   ─────────────────────────────────────────────────────────────────────────────
   -15°C to -25°C                    • OPV (At National & Regional Bulk Depots)
   (Deep Freeze)
   ─────────────────────────────────────────────────────────────────────────────
   +2°C to +8°C                      • ALL VACCINES at Health Center / Dispensary level
   (Standard Refrigerator Target)    • Pentavalent, PCV-10, Td, HPV, HepB
                                     • BCG, MR, Yellow Fever, ROTAVAC, IPV
   ─────────────────────────────────────────────────────────────────────────────
   > +8°C                            • Cold chain breach: High risk of heat inactivation
   < +2°C                            • Freezing breach: Destroys aluminum-adsorbed vaccines!

Facility Refrigerator Management

• Target Temperature: Maintained strictly between +2.0°C and +8.0°C.
• Temperature Monitoring: Read twice daily (morning at 08:00 and evening at 16:00, including weekends and public holidays) using a calibrated 30-day electronic temperature logger (Fridge-tag 2) or alcohol thermometer mounted in the middle shelf. Recorded on a standardized MOH 335 Temperature Chart.
• Storage Layout Rules:
  • Top Shelf / Freezer Compartment: Ice packs for conditioning; OPV may be frozen only at bulk depots.
  • Upper / Middle Shelves (+2°C to +4°C): Heat-sensitive, freeze-tolerant live viral vaccines (OPV, Measles-Rubella, BCG, Yellow Fever).
  • Lower Shelves (+4°C to +8°C): Freeze-sensitive, aluminum-adsorbed vaccines (Pentavalent, PCV-10, Td, HPV, HepB, IPV).
  • Bottom Shelf / Crisper: Filled with chilled bottles of water to stabilize interior temperature during power outages. Never place vaccines in the door compartments or bottom crisper.

---

4. Freeze Sensitivity & The Shake Test Protocol

Freeze-Sensitive vs. Freeze-Tolerant Vaccines

   FREEZE-SENSITIVE VACCINES               FREEZE-TOLERANT VACCINES
   (NEVER ALLOW TO FREEZE!)               (Can withstand freezing)
   ───────────────────────────────         ──────────────────────────────
   • Pentavalent (DTP-HepB-Hib)            • OPV (Oral Poliovirus)
   • PCV-10 (Pneumococcal)                 • BCG (Freeze-dried)
   • Td / TT (Tetanus Toxoid)              • Measles-Rubella (Lyophilized)
   • HPV (Human Papillomavirus)            • Yellow Fever (Lyophilized)
   • Hepatitis B
   • IPV (Inactivated Polio)

Pathophysiology of Freeze Damage: Vaccines containing aluminum adjuvants (aluminum hydroxide or aluminum phosphate) form a delicate colloidal suspension. If frozen below 0°C, ice crystals crush the aluminum lattice, irreversibly breaking the bond between the adjuvant and the microbial antigen. The adjuvant forms heavy, insoluble granules that fall out of suspension, permanently destroying vaccine immunogenicity and markedly increasing the risk of sterile subcutaneous abscesses.

The Shake Test Step-by-Step Protocol

When a refrigerator breaches < 0°C or freeze-indicators (Freeze-tag / Freeze-check) trigger, the clinician must conduct the Shake Test before discarding suspected vials:

SHAKE TEST WORKFLOW:

[Step 1: PREPARE CONTROL VIAL]
  • Take a vial of the identical vaccine from the same manufacturer and lot number.
  • Deliberately freeze it solid at -20°C for 24 hours, then thaw completely at room temperature.
  • Clearly mark it: "FROZEN CONTROL".
         │
         ▼
[Step 2: SELECT TEST VIAL]
  • Take the suspected vial from the compromised refrigerator.
         │
         ▼
[Step 3: SHAKE TOGETHER]
  • Hold both vials in one hand and shake vigorously for 10 to 15 seconds.
         │
         ▼
[Step 4: OBSERVE SEDIMENTATION]
  • Place both vials side by side on a flat, well-lit surface.
  • Observe settling behavior at 5, 15, and 30 minutes.
         │
         ▼
[Step 5: INTERPRETATION]
  • TEST VIAL SETTLES SLOWLY (Remains cloudy much longer than control):
    ► PASSED: Vaccine was NOT freeze-damaged -> Safe to use.
  • TEST VIAL SETTLES RAPIDLY (Sediments and clears at same rate or faster than control):
    ► FAILED: Vaccine WAS frozen and damaged -> DISCARD IMMEDIATELY.

---

5. Vaccine Vial Monitor (VVM) & Multi-Dose Vial Policy

Vaccine Vial Monitor (VVM) Stages

The VVM is a temperature-sensitive label comprising an inner white square surrounded by an outer purple reference circle. It reflects cumulative heat exposure over time.

Exam Key: Even if the manufacturer's calendar expiration date stamped on the vial has not passed, a vial with a VVM at Stage 3 or Stage 4 must be destroyed immediately.

Multi-Dose Vial Policy (MDVP)

The Kenya NVIP distinguishes between opened multi-dose vials of liquid injectable vaccines versus reconstituted lyophilized vaccines:

1. Reconstituted Freeze-Dried Vaccines (BCG, Measles-Rubella, Yellow Fever):
   • Strict Rule: Must be DISCARDED within 6 hours of reconstitution or at the end of the immunization session, whichever comes first.
   • Rationale: These vaccines contain no antimicrobial preservatives. Unused reconstituted vials are prone to Staphylococcus aureus colonization, which can cause fatal pediatric Toxic Shock Syndrome (TSS).
2. Liquid Injectable Vaccines (Pentavalent, PCV-10, OPV, Td, IPV):
   • Opened vials may be retained and used for up to 28 days, provided that:
     • The expiration date has not passed.
     • Stored continuously between +2°C and +8°C.
     • The VVM has not reached Stage 3 or 4.
     • The vial septum was not submerged in water and strict aseptic technique was maintained.